Cite
HARVARD Citation
Domenyuk, V. et al. (n.d.). P-132Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets. Annals of oncology. p. . [Online].